Stemtech: The Category Leader in Adult Stem Cell Nutrition Products

Did you know that by 2030, 1 in 6 people globally will be 60 or older? Going back to 2020, the number of people aged 60 years and older already outnumbered children younger than 5 years ! Whether we like it or not, the world is aging faster than ever before.

Despite how scary this sounds, it also means more people are looking for ways to live longer, healthier and happier lives.

There are many things said to combat the effects of aging. One of the most effective being reorienting one’s lifestyle to increase the consumption of all natural, plant-based products that help increase your body’s ability to fight back against getting older.

Enter Stemtech, a leading direct marketing organization focused on the research, sale and distribution of category defining adult stem cell nutrition products, also known as stemceuticals™.

Summary

👉 Turning Back the Clock with Stemceuticals

👉 Driven By Science, Powered by Dreams

👉 Not Your Average Network Marketer

👉 The Bottom Line

Turning Back the Clock Using your own Adult Stem Cells

Everyone knows getting old sucks. That’s why multibillion-dollar industries have been established to help combat it. There’s lots of discussion about the things that contribute to aging. Stem Cells should be centre stage in the discussion.

Stem cells have the unique ability to self-renew and turn into other cell types. This makes them critical for maintaining tissue and regeneration.

Stem cells have the ability to maintain telomere length, even after multiple cell divisions. This unique property allows them to continue replenishing the body’s specialized cells (even as we age) so they can play a crucial role in maintaining tissue health and function. The bad news is, that as we get older, the amount of stem cells our body releases falls off a cliff.

Stem cells play a vital role in preserving the information in our genome and may have influence over part of our biological clock (e.g., lifespan of cells ), it’s no wonder that the Stem Cell Nutrition and Stem Cell Therapy market is expected to top $25.8 billion by 2027 .

Driven By Science, Powered by Dreams

Founded in 2005, Stemtech is at the forefront of all-natural plant-based, anti-aging, and longevity products derived from the power of adult Stem cells. Since its founding, the company has done over $600 million in cumulative sales and holds or licenses six patents across the U.S, Mexico, Australia, and Malaysia. Given all this success, the company’s claims of category leadership in the adult stem cell product space are impossible to dispute.

Backed by patented technology and research, the organization’s diversified product portfolio targets five of the most important aspects of stem cell physiology, including the release of stem cells, their circulation in the blood, and their migration into tissues. All in the name of emphasizing cell renewal, rejuvenation, and anti-aging.

Stemtech’s unique and diverse product portfolio are composed of clinically documented natural botanicals and other ingredients that support the performance of adult stem cells, rather than containing stem cells themselves.

These unique offerings supported by a longstanding network marketing distribution model of over 12,000 partners has enabled the organization to land a top spot on the Inc 5000 list of fastest growing companies a whopping 4 times.

The company is also backed by some of the network marketing and health supplement industry’s vets like Charles Arnold, John W. Meyer, Darryl Green, and Network Marketing Hall of Fame Member and Stemtech Founding Independent Business Partner (IBP), Izzy Matos, so you know that those steering the ship have the right head on their shoulders.

Not Your Average Network Marketer

Longevity isn’t easy in network marketing and being around for so long is one of the biggest things that makes Stemtech stand out. The company has a committed base of IBPs and customers.

Lack of investment in distribution and product sustainability are at the heart of what makes most network marketing organizations fail and Stemtech has proactively approached these problems differently to make sure it’s around for the long haul.

Building a direct sales model company that prioritizes the success of its distributors has been the driving force. Unlike those who didn’t make the cut in network marketing, Stemtech provides ongoing training and guidance through weekly seminars, emphasizing distributors relationships, the creation of practical marketing tools, like back-office support, community groups and a proprietary mobile app to ensure its IBPs can succeed.

Stemtech has also structured its distributor compensation plan differently than other network marketing organizations and doesn’t use breakaway plans, which were common in the early days of network marketing. Each of these factors underlie what make Stemtech special as both a leader in network marketing and the adult stem cell product space.

Is this the next Herbalife ($1.5 billion market cap)?

The Bottom Line

Starting 2023, the company is at an inflection point.

Having just raised $7 million , Stemtech is going all in on its Vision 2023 growth plan. Near term catalysts include the strengthening of its inventory and logistics, business partner commission structure, expansion into new global markets (Japan, Colombia, and Malaysia), expanding third-party manufacturing, and the build out of its e-commerce strategy.

The company is also looking to expand Research and Development to fill its pipeline of future products. This multi-pronged approach is set to further Stemtech’s category leadership position.

Get ready. We sure are.

To learn more about Stemtech here!

Gritcapital.substack.com (“Grit”) is a website owned and operated by Substack. Grit is paid fees by the companies that make investment offerings on this website. Be aware that payment of these fees may put Grit in a conflict of interest with the investor. By accessing this website or any page thereof, you agree to be bound by the Terms of Use and Privacy Policy, in effect at the time you access this website or any page thereof. The Terms of Use and Privacy Policy may be amended from time to time. Nothing on this website shall constitute an offer to sell, or a solicitation of an offer to buy or subscribe for, any securities to any person in any jurisdiction where such an offer or solicitation is against the law or to anyone to whom it is unlawful to make such offer or solicitation. Grit is not an underwriter, broker-dealer, Title III crowdfunding portal or a valuation service and does not engage in any activities requiring any such registration. Grit does not provide advice on investments or structure transactions. Offerings made under Regulation A under the U.S. Securities Act of 1933, as amended (the “Securities Act”) are available to U.S. investors who are “accredited investors” as defined by Rule 501 of Regulation D under the Securities Act well as non-accredited investors, who are subject to certain investment limitations as set forth in Regulation A under the Securities Act. In order to invest in Regulation A offerings, investors may be asked to fill out a certification and provide necessary documentation as proof of your income and/or net worth to verify that you are qualified to invest in offerings posted on this website. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. Grit does not verify the adequacy, accuracy or completeness of any information. Neither Grit nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, valuations of securities or completeness of any information on this site or the use of information on this site. Neither Grit nor any of its directors, officers, employees, representatives, affiliates or agents shall have any liability whatsoever arising from any error or incompleteness of fact, or lack of care in the preparation of, any of the materials posted on this website. Investing in securities, especially those issued by start-up companies, involves substantial risk. investors should be able to bear the loss of their entire investment and should make their own determination of whether or not to make any investment based on their own independent evaluation and analysis.

The information contained on this website has been prepared by the paid advertiser Stemtech Corporation. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser. Stemtech Corporation has paid $90,000 to have this content (in addition to other content on other social media sites) created and published. GetVersed is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.

The information contained on this website has been prepared by the paid advertiser. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser.

Grit Capital Corporation is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.

THE INFORMATION CONTAINED ON THIS WEBSITE IS NOT AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, AND DOES NOT PURPORT TO BE AND DOES NOT EXPRESS ANY OPINION AS TO THE PRICE AT WHICH THE SECURITIES OF ANY COMPANY MAY TRADE AT ANY TIME. THE INFORMATION AND OPINIONS PROVIDED HEREIN SHOULD NOT BE TAKEN AS SPECIFIC ADVICE ON THE MERITS OF ANY INVESTMENT DECISION. INVESTORS SHOULD MAKE THEIR OWN INVESTIGATION AND DECISIONS REGARDING THE PROSPECTS OF ANY COMPANY DISCUSSED HEREIN BASED ON SUCH INVESTORS’ OWN REVIEW OF PUBLICLY AVAILABLE INFORMATION AND SHOULD NOT RELY ON THE INFORMATION CONTAINED HEREIN. INVESTORS SHOULD OBTAIN INDIVIDUAL FINANCIAL ADVICE BASED ON THEIR OWN CIRCUMSTANCES BEFORE MAKING AN INVESTMENT DECISION.

No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned.

Any projections, market outlooks or estimates herein are forward looking statements and are inherently unreliable. They are based upon certain assumptions and should not be construed to be indicative of the actual events that will occur. Other events that were not taken into account may occur and may significantly affect the returns or performance of the securities discussed herein. The information provided herein is based on matters as they exist as of the date of preparation and not as of any future date, and the publisher undertakes no obligation to correct, update or revise the information in this document or to otherwise provide any additional material.

The publisher, its affiliates, and clients of the publisher or its affiliates may currently have long or short positions in the securities of the companies mentioned herein, or may have such a position in the future (and therefore may profit from fluctuations in the trading price of the securities). To the extent such persons do have such positions, there is no guarantee that such persons will maintain such positions.

Neither the publisher nor any of its affiliates accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein.